Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposomal
- Development stage
- Phase 1
- Lead developer
- CSPC ZhongQi Pharmaceutical Technology
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mitoxantrone hydrochloride liposomal is a liposome-encapsulated formulation of the anthracenedione antineoplastic agent mitoxantrone. It acts primarily as a DNA intercalator and an inhibitor of topoisomerase II, leading to DNA strand breaks and inhibition of DNA synthesis and repair. The liposomal delivery system is designed to enhance the drug's accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect while reducing systemic toxicities, particularly the cumulative cardiotoxicity associated with conventional mitoxantrone. Developed by CSPC Pharmaceutical Group, with clinical research support from institutions like the Affiliated Hospital of Hebei University, it was first approved in China in 2022 for the treatment of peripheral T-cell lymphoma and is currently being investigated for various solid tumors and other hematological malignancies.
- Brand names
- Duoenda
- Other names
- mitoxantrone hydrochloride (liposomal)mitoxantrone liposome injectionliposomal mitoxantrone hydrochloride
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposomal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposomal.